We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Tobacco smoking and medical co-morbidities among patients with schizophrenia in a Nigerian clinical setting.
African Journal of Medicine and Medical Sciences 2014 December
BACKGROUND: Smoking is highly prevalent in patients living with schizophrenia and is associated with medical and psychiatric morbidities
METHODS: In this descriptive, consecutive patients with schizophrenia (368) were interviewed at State Hospital Ibadan between January and December 2008. Information on demography and tobacco smoking, medication adherence and self reports of chronic common health conditions were obtained. The PANSS was used to determine level of psychopathology. Univariate associations were determined using Chi square statistics and multivariate analysis was used for further exploration of variables that were significant during univariate analysis. All analyses were performed using the SPSS (17.0).
RESULTS: Prevalence of lifetime tobacco use was 198 (53.8%), current use 122 (33.1%). Current use was highest in respondents less than 25 years of age X2 = 11.8, p = 0.003 and reduced with increasing education, X2 = 21.6, p = 0.00, higher in non medication adherent patients, X2 = 19.9, p = 0.00 and was associated with health conditions such as haemopoetic diseases X2 = 6.8, p = 0.01 and respiratory diseases. Mean score of positive, negative, general psychopathology, total psychopathology subscales of PANSS were respectively significantly higher among current user, compared with abstainers, t = 6.7, p = 0.00, t = 5.1, p = 0.00, t 6.2, p.= 0.00, t 6.7, p = 0.00. Only general psychopathology subscale of PANSS, OR = 3.5, 95% CI (1.2-6.5), p = 0.02 remained associated with current tobacco use after adjusting for gender.
CONCLUSION: The present study demonstrates high rate of tobacco use in patients with schizophrenia. Thus, such patients require additional screening for tobacco and tobacco cessation program.
METHODS: In this descriptive, consecutive patients with schizophrenia (368) were interviewed at State Hospital Ibadan between January and December 2008. Information on demography and tobacco smoking, medication adherence and self reports of chronic common health conditions were obtained. The PANSS was used to determine level of psychopathology. Univariate associations were determined using Chi square statistics and multivariate analysis was used for further exploration of variables that were significant during univariate analysis. All analyses were performed using the SPSS (17.0).
RESULTS: Prevalence of lifetime tobacco use was 198 (53.8%), current use 122 (33.1%). Current use was highest in respondents less than 25 years of age X2 = 11.8, p = 0.003 and reduced with increasing education, X2 = 21.6, p = 0.00, higher in non medication adherent patients, X2 = 19.9, p = 0.00 and was associated with health conditions such as haemopoetic diseases X2 = 6.8, p = 0.01 and respiratory diseases. Mean score of positive, negative, general psychopathology, total psychopathology subscales of PANSS were respectively significantly higher among current user, compared with abstainers, t = 6.7, p = 0.00, t = 5.1, p = 0.00, t 6.2, p.= 0.00, t 6.7, p = 0.00. Only general psychopathology subscale of PANSS, OR = 3.5, 95% CI (1.2-6.5), p = 0.02 remained associated with current tobacco use after adjusting for gender.
CONCLUSION: The present study demonstrates high rate of tobacco use in patients with schizophrenia. Thus, such patients require additional screening for tobacco and tobacco cessation program.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app